For the average person, living at high altitude-where oxygen is sparser than at sea level-can have health benefits ranging ...

I really love those mittens. It seems like they have been in my life forever, or at least for every winter since the 1990s. Black brushed-leather outside, plush felt inside, they fit my hands like ...

Cord Coffey, of Cogar, Okla., guides cattle toward a holding pen at the Oklahoma National Stockyards Tuesday, Jan. 14, 2025, in Oklahoma City. (AP Photo/Julio Cortez) ...

Obesity biotech Metsera and renal and metabolic-focused Maze Therapeutics have met their IPO expectations as the two companies prepare to join the Nasdaq this morning. While Metsera is offering ...

Metsera and Maze Therapeutics are the second and third biotechnology firms this year to go public, raising $275 million and $140 million, respectively, in a pair of new stock offerings priced Thursday ...

Inside a vast convention center hall, impossibly shiny cars stretched out before me in a vast maze that seemed to hold surprises around ... When you’re a kid in the Mitten State, there are a lot of ...

Maze Therapeutics has set out plans for a $131 million IPO as the company prepares to start dosing its lead kidney drug in a phase 2 trial. The Bay Area-based biotech unveiled its ambition earlier ...

Maze seeks as much as $133 mln in New York IPO Backers include Alphabet's GV and Third Rock Ventures Biotech IPOs set for ramp up in coming weeks Jan 27 (Reuters) - Drug developer Maze ...